ATE441435T1 - Gegen hiv-1 gp120 envelope glykoprotein gerichtete rekombinant-immunotoxin - Google Patents
Gegen hiv-1 gp120 envelope glykoprotein gerichtete rekombinant-immunotoxinInfo
- Publication number
- ATE441435T1 ATE441435T1 AT99930180T AT99930180T ATE441435T1 AT E441435 T1 ATE441435 T1 AT E441435T1 AT 99930180 T AT99930180 T AT 99930180T AT 99930180 T AT99930180 T AT 99930180T AT E441435 T1 ATE441435 T1 AT E441435T1
- Authority
- AT
- Austria
- Prior art keywords
- directed against
- envelope glycoprotein
- against hiv
- immunotoxin
- recombinant immunotoxin
- Prior art date
Links
- 101710121417 Envelope glycoprotein Proteins 0.000 title 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 title 1
- 102100021696 Syncytin-1 Human genes 0.000 title 1
- 229940051173 recombinant immunotoxin Drugs 0.000 title 1
- 239000002596 immunotoxin Substances 0.000 abstract 3
- 229940051026 immunotoxin Drugs 0.000 abstract 3
- 230000002637 immunotoxin Effects 0.000 abstract 3
- 231100000608 immunotoxin Toxicity 0.000 abstract 3
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 abstract 2
- 101710132601 Capsid protein Proteins 0.000 abstract 1
- 101710094648 Coat protein Proteins 0.000 abstract 1
- 101710112752 Cytotoxin Proteins 0.000 abstract 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 abstract 1
- 101710125418 Major capsid protein Proteins 0.000 abstract 1
- 101710141454 Nucleoprotein Proteins 0.000 abstract 1
- 101710083689 Probable capsid protein Proteins 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 239000002619 cytotoxin Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
- A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8886098P | 1998-06-11 | 1998-06-11 | |
PCT/US1999/012909 WO1999064073A2 (en) | 1998-06-11 | 1999-06-08 | Recombinant immunotoxin directed against the hiv-1 gp120 envelope glycoprotein |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE441435T1 true ATE441435T1 (de) | 2009-09-15 |
Family
ID=22213913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99930180T ATE441435T1 (de) | 1998-06-11 | 1999-06-08 | Gegen hiv-1 gp120 envelope glykoprotein gerichtete rekombinant-immunotoxin |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1085908B1 (de) |
AT (1) | ATE441435T1 (de) |
AU (1) | AU763118B2 (de) |
CA (1) | CA2334745A1 (de) |
DE (1) | DE69941358D1 (de) |
WO (1) | WO1999064073A2 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115262B1 (en) | 1999-03-16 | 2006-10-03 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric protein for prevention and treatment of HIV infection |
GB9925966D0 (en) | 1999-11-02 | 1999-12-29 | Petrik Juraj | Threapeutic vaccines against variable viruses and other targets |
US8043621B2 (en) * | 2007-05-10 | 2011-10-25 | Ramot At Tel Aviv University Ltd. | Recombinant fusion protein and polynucleotide construct for immunotoxin production |
US8597655B2 (en) | 2007-05-10 | 2013-12-03 | Ramot At Tel-Aviv University Ltd. | Recombinant fusion protein and polynucleotide construct for immunotoxin production |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834599A (en) * | 1987-05-29 | 1998-11-10 | Tanox Biosystems, Inc. | Immunoconjugates which neutralize HIV-1 infection |
US5458878A (en) * | 1990-01-02 | 1995-10-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity |
AU706056B2 (en) * | 1995-10-13 | 1999-06-10 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Immunotoxin containing a disulfide-stabilized antibody fragment |
-
1999
- 1999-06-08 AU AU46772/99A patent/AU763118B2/en not_active Ceased
- 1999-06-08 DE DE69941358T patent/DE69941358D1/de not_active Expired - Lifetime
- 1999-06-08 AT AT99930180T patent/ATE441435T1/de not_active IP Right Cessation
- 1999-06-08 WO PCT/US1999/012909 patent/WO1999064073A2/en active IP Right Grant
- 1999-06-08 CA CA002334745A patent/CA2334745A1/en not_active Abandoned
- 1999-06-08 EP EP99930180A patent/EP1085908B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1085908A2 (de) | 2001-03-28 |
DE69941358D1 (de) | 2009-10-15 |
WO1999064073A9 (en) | 2000-04-27 |
AU4677299A (en) | 1999-12-30 |
CA2334745A1 (en) | 1999-12-16 |
WO1999064073A3 (en) | 2000-02-10 |
AU763118B2 (en) | 2003-07-10 |
WO1999064073A2 (en) | 1999-12-16 |
EP1085908B1 (de) | 2009-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200501810A1 (ru) | Композиция конъюгированного лекарственного средства | |
CY1117756T1 (el) | Χιμαιρικα υβριδια μονομερους-διμερους ανοσοσφαιρινης | |
ATE533784T1 (de) | Lösliche, einzelkettige proteine des t- zellrezeptors | |
CY1108007T1 (el) | Φαρμακευτικες συνθεσεις βοτουλινικης τοξινης | |
ATE389721T1 (de) | Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen | |
PT778891E (pt) | Anticorpo monoclonal recombinante anti-rhesus d (d7c2) | |
WO2003000877A3 (en) | A soluble complex comprising a retroviral surface glycoprotein | |
CY1108799T1 (el) | Αντισωμα αντι- ccr5 | |
CO5280086A1 (es) | Molecula de enlace de cd154, construccion de adn, vector de expresion, composcion y combinacion farmaceutica | |
PE20001316A1 (es) | Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene | |
DE69629580D1 (de) | Immunotoxin enthaltend ein disulfid-stabilisiertes antikörperfragment | |
PE20090046A1 (es) | Anticuerpo recombinante humanizado anti-interleuquina 10 | |
PT724456E (pt) | Anticorpos contra cd4 | |
DE69632256D1 (de) | Antivirale proteine, dafür kodierende dna, und deren verwendung | |
WO1998055150A8 (en) | Txu-7-pap immunotoxin and use thereof | |
EA200300983A1 (ru) | Растворимый гетеродимерный рецептор цитокина | |
ATE238420T1 (de) | Rekombinanter humanisierter antikörper gegen menschlichen immunschwächevirus | |
ATE441435T1 (de) | Gegen hiv-1 gp120 envelope glykoprotein gerichtete rekombinant-immunotoxin | |
WO2006044410A3 (en) | A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines | |
BRPI9709524B8 (pt) | processo para a produção de um anticorpo para células t que expressam cd4 | |
DE60141297D1 (de) | Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper | |
WO2003015702A3 (en) | Epitopes of human immunodeficiency virus-1 | |
WO2003011907A3 (de) | Rezeptor, dessen verwendung sowie mausantikörper | |
DE59608073D1 (de) | Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid | |
WO1996041608A3 (en) | Pyrularia thionin containing immunotoxins and immunotoxin-like conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |